AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 292 min read$ZLAB

Du Ying sold $429K of ZLAB

Du Ying (Chairperson & CEO) sold 24,543 shares of Zai Lab Ltd (ZLAB) at $17.46 ($0.43M total) on 2026-06-26.

Original reporting
SEC EDGAR · Du Ying
Published Jun 29, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ZLAB
Neutral
medium confidence
Mentioned
$ZLAB
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZLABNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or correlate with upcoming company catalysts, but this specific disclosure alone doesn’t change the company’s outlook based on the provided text.

02

Market read

A newly filed insider sale can marginally affect sentiment, but the text lacks any fundamental trigger (earnings, trial data, guidance, or regulatory action).

03

What to watch

The article doesn’t state tax/financing needs, diversification targets, or whether other insiders sold/bought around the same time, limiting inference.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-29 after-hours; reflects insider sale executed 2026-06-26.

Background

The article is a SEC Form 4 insider transaction disclosure for Zai Lab Ltd, reporting an open-market sale by CEO/Chair Du Ying.

Company-level read

Ticker impact

$ZLABNeutralMedium confidence
Context

Zai Lab CEO/Chair Du Ying sold 24,543 shares on 2026-06-26 for about $428.5K, disclosed via a fresh Form 4 filing.

Expected impact

Low near-term impact; any reaction is likely limited to sentiment/positioning rather than fundamentals.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction is an open-market sale and the article provides no accompanying operational/regulatory/clinical catalyst.

Market effects

Sector

Minimal; single-company insider transaction without sector-wide signal.

Regional

Minimal; US-listed ADR/stock sentiment only.

Global

Minimal; no deal/regulatory/clinical spillover described.

Counterpoint

What could challenge this read

Insider sales are often liquidity-driven; absence of a stated 10b5-1 plan doesn’t necessarily imply negative fundamentals.

Key entities

  • issuer
    Zai Lab Ltd

    Subject of the Form 4 insider transaction; CEO/Chair Du Ying sold shares on 2026-06-26.

  • insider
    Du Ying

    Chairperson & CEO; reported open-market sale of 24,543 shares at $17.4610 on 2026-06-26.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ZLAB insider trading history →

Related articles

OCT 23
$ZLABMedAI 8/10

Zai Lab’s Zoci Shows 82% Response Rate in Early Lung Cancer Study

Zai Lab's (ZLAB) experimental drug Zoci showed an 82% response rate in an early lung cancer study. The 1.6 mg/kg cohort had 81.9% six-month progression-free survival. Zoci with atezolizumab and carboplatin had a 92.3% response rate but increased toxicity. Zai Lab plans a global Phase III study by 2026, aiming to replace chemotherapy in frontline treatment. The company expects multiple program readouts and a potential U.S. biologics license application submission next year.

finance.yahoo.com2 min
OCT 23
$ZLABHighAI 9/10

Why is Zai Lab stock surging today?

Zai Lab (ZLAB) stock rose 7.2% to $23.62 after releasing Phase 1b trial data for its oncology drug zocilurtatug pelitecan, showing an 81.8% response rate. The company also announced a $250M capital raise from institutional investors. Analysts have an average price target above current levels.

investing.com2 min
OCT 23
$ZLABMedAI 8/10

Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab (ZLAB) reported positive Phase 1b trial results for zocilurtatug pelitecan (zoci) plus atezolizumab in extensive-stage small cell lung cancer (ES-SCLC). The combination achieved an 81.8% response rate and 81.9% 6-month progression-free survival rate. The therapy was well-tolerated, with Grade >3 adverse events in 9.1% of patients. Zai Lab plans to initiate a global Phase 3 trial by year-end 2026.

thailand-business-news.com3 min
OCT 23
$ZLABMedAI 9/10

Zai Lab Limited: Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab's (ZLAB) drug zocilurtatug pelitecan (zoci) showed 81.8% response rate and 81.9% 6-month progression-free survival in a Phase 1b trial for extensive-stage small cell lung cancer. The combination with atezolizumab was well-tolerated. A Phase 3 trial is planned for 2026. Zai Lab will discuss the data in an investor call.

finanznachrichten.de3 min
OCT 23
$ZLABHighAI 9/10

Zai Lab reports phase 1b trial data for lung cancer treatment

Zai Lab (ZLAB, 9688) reported Phase 1b trial data for zocilurtatug pelitecan with atezolizumab in lung cancer treatment. At 1.6 mg/kg, 81.8% response rate and 81.9% six-month progression-free survival were observed. Adverse events were mostly mild. A triplet regimen showed 92.3% response rate but higher severe adverse events. Zai Lab plans a Phase 3 study by year-end 2026.

investing.com2 min